Pharvaris (NASDAQ:PHVS – Get Rating) and Larimar Therapeutics (NASDAQ:LRMR – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.
This table compares Pharvaris and Larimar Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Pharvaris and Larimar Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Larimar Therapeutics||N/A||N/A||-$50.64 million||($1.83)||-2.38|
This is a summary of recent recommendations and price targets for Pharvaris and Larimar Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Pharvaris presently has a consensus target price of $17.33, suggesting a potential upside of 69.11%. Larimar Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 101.15%. Given Larimar Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Larimar Therapeutics is more favorable than Pharvaris.
Insider & Institutional Ownership
70.1% of Pharvaris shares are owned by institutional investors. 6.7% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility & Risk
Pharvaris has a beta of -4.83, suggesting that its stock price is 583% less volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
About Larimar Therapeutics
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich’s ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.